ATMI Reports Growth in Revenues and Net Income for the First Quarter of 2013

company logo

DANBURY, Conn., April 24, 2013 (GLOBE NEWSWIRE) -- ATMI, Inc. (Nasdaq:ATMI), a global technology company, today reported revenues and net income for the first quarter of 2013.

Revenues during the first quarter of 2013 were $99.4 million, a 7 percent increase compared with $92.6 million during the same period last year. Net income was $8.4 million, or $0.26 per diluted share, compared with $3.9 million, or $0.12 per diluted share, during the first quarter of 2012.

"We achieved solid revenue growth, despite a challenging demand environment in Microelectronics, due to growth in implant and strong demand for single-use biopharmaceutical products," said Chief Executive Officer Doug Neugold. "Implant benefitted from a full quarter of the SDS® Direct transaction, which was transitioning during the first quarter of last year. This was partially offset by material-usage improvements by our customers in copper materials, resulting in modest Microelectronics growth. LifeSciences growth was strong, climbing 24 percent on increased equipment and consumable sales."

Total operating expense decreased 4 percent to $36.4 million due to planned spending reductions and effective cost management. Two significant items during the quarter were the recognition of $0.03 per diluted share of employee separation costs offset by $0.03 per diluted share for tax benefits related to certain 2012 retroactive provisions.

First Quarter 2013 Segment Results


  • Revenues were $88.1 million, up 6 percent compared with last year
  • Growth in implant offset material-usage improvements by customers for our copper materials
  • Operating income was $25.2 million, an increase of 20 percent due to lower operating expense


  • Revenues improved 24 percent compared with last year to $11.3 million
  • Continued demand for single-use products drove the improvement, with strong growth in both equipment and consumables
  • Operating loss of $1.3 million compared with a loss of $2.1 million last year

Market Environment

"We are becoming more confident in our 2013 growth outlook," commented Neugold. "Our expectation of modest wafer start growth, with a majority of it occurring during the second and third quarters of the year, seems to be confirmed by customer commentary and industry analysis. While it is clear that advanced devices for mobility applications have momentum, there is commentary that indicates some segments are not as strong. Even with this mix in demand trends for various devices, our focus on the leading edge should allow us to outgrow the market. LifeSciences has begun the year on a strong note, and we expect this will continue throughout the year, with some possible near-term fluctuations associated with customers' ramp patterns for this new technology. As volumes improve, and we maintain our focus on profitability and cash management, we anticipate results will improve through the year."

Webcast Information

A conference call (dial-in: 877.766.0748) discussing the Company's financial results and business outlook will begin at 11:00 a.m. Eastern time, April 24, 2013. A replay of the call will be available for 48 hours at 855.859.2056 (access code 93693894). The call can also be accessed live and on-demand from the ATMI Investor Relations website at A copy of management's presentation materials will be available on the ATMI Investor Relations website before the call.

About ATMI

ATMI, Inc. provides specialty semiconductor materials, and safe, high-purity materials handling and delivery solutions designed to increase process efficiencies for the worldwide semiconductor, flat panel, and life sciences industries. For more information, please visit

ATMI, the ATMI logo, and SDS are trademarks or registered trademarks of Advanced Technology Materials, Inc., in the United States, other countries, or both.

Forward Looking Statements

Statements contained herein that relate to ATMI's future performance, including, without limitation, statements with respect to ATMI's anticipated results of operations or level of business for 2013 or any other future period, are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations only and are subject to certain risks, uncertainties, and assumptions, including, but not limited to, changes in semiconductor and life sciences industry growth (including, without limitation, wafer starts) or ATMI's markets; competition, problems, or delays developing, commercializing, and delivering new products; customer-driven pricing pressure; potential loss of key customers; problems or delays in integrating acquired operations and businesses; uncertainty in the credit and financial markets; ability to protect ATMI's proprietary technology; and other factors described in ATMI's Form 10-K for the year ended December 31, 2012 and other subsequent filings with the Securities and Exchange Commission. Such risks and uncertainties may cause actual results to differ materially from those expressed in our forward-looking statements. ATMI undertakes no obligation to update any forward-looking statements.

(in thousands, except per share data)
Three Months Ended
March 31,
2013 2012
(Unaudited) (Unaudited)
Revenues $ 99,407 $ 92,574
Cost of revenues 52,720 48,392
Gross profit 46,687 44,182
Operating expenses:
Research and development 13,182 14,489
Selling, general and administrative 23,168 23,546
Total operating expenses 36,350 38,035
Operating income 10,337 6,147
Interest income 354 325
Other income (expense), net 373 (306)
Income before income taxes 11,064 6,166
Provision for income taxes 2,638 2,304
Net income $ 8,426 $ 3,862
Earnings per diluted share $ 0.26 $ 0.12
Weighted average shares outstanding - diluted 32,709 32,842
Comprehensive income $ 6,548 $ 237
(in thousands)
March 31, December 31,
2013 2012
Cash & marketable securities (1) $142,834 $156,447
Accounts receivable, net 63,427 60,806
Inventories, net 91,046 87,555
Other current assets 34,970 25,736
Total current assets 332,277 330,544
Property, plant, and equipment, net 125,956 125,099
Marketable securities, non-current (1) 8,240 12,073
Other assets 128,603 131,437
Total assets $595,076 $599,153
Liabilities and stockholders' equity
Accounts payable 35,541 $38,573
Other current liabilities 34,268 36,329
Total current liabilities 69,809 74,902
Non-current liabilities 15,760 16,975
Stockholders' equity 509,507 507,276
Total liabilities & stockholders' equity $595,076 $599,153
(1) Total cash and marketable securities equaled $151.1 million and $168.5 million at March 31, 2013 and December 31, 2012, respectively.
Segment Results
(in thousands)
Three Months Ended
March 31,
2013 2012
Microelectronics $ 88,111 $ 83,465
LifeSciences 11,281 9,109
All Other 15 --
Total Consolidated $ 99,407 $ 92,574
Operating income (loss)
Three Months Ended
March 31,
2013 2012
Microelectronics $ 25,242 $ 21,032
LifeSciences (1,258) (2,126)
All Other (13,647) (12,759)
Total Consolidated $ 10,337 $ 6,147

CONTACT: Troy Dewar Director, Investor Relations 203.207.9349

Source:ATMI, Inc.